Hodgkin lymphoma – Medxy AI

Early ctDNA MRD After Two Cycles Identifies Distinct Relapse Risk Groups in Advanced Hodgkin Lymphoma

By MedXY 05/14/2026

In the GHSG HD21 trial, a validated ctDNA assay showed that MRD positivity after two treatment cycles strongly predicted inferior progression-free survival and improved early risk stratification, especially when combined with interim PET.

Hematology-Oncology news Specialties

PET-Guided BrECADD Therapy: A Breakthrough for Older Patients with Advanced-Stage Classic Hodgkin Lymphoma

By MedXY 09/21/2025

This phase II HD21 trial cohort demonstrates that PET-guided BrECADD chemotherapy is feasible, effective, and well-tolerated in older patients with advanced-stage classic Hodgkin lymphoma, achieving high complete remission and survival rates.

Clinical Updates Hematology-Oncology news Specialties

Fertility Outcomes in Advanced-Stage Classic Hodgkin Lymphoma: BrECADD Versus eBEACOPP in the HD21 Trial

By MedXY 08/02/2025

The HD21 trial shows BrECADD offers superior gonadal function recovery and higher parenthood rates, especially in men, compared with eBEACOPP for advanced-stage classic Hodgkin lymphoma, supporting BrECADD as the preferred first-line therapy for fertility preservation.